#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-13	Relationships	_
1-2	14-21	between	_
1-3	22-30	abnormal	_
1-4	31-37	neural	_
1-5	38-48	activities	_
1-6	49-52	and	_
1-7	53-62	cognitive	_
1-8	63-74	impairments	_
1-9	75-77	in	_
1-10	78-86	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-11	87-91	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-12	92-102	drug-naive	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-13	103-116	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-14	117-130	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-15	131-141	Background	_
1-16	142-147	Prior	_
1-17	148-155	resting	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-18	156-161	state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-19	162-172	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-20	173-181	Magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-21	182-191	Resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-22	192-199	Imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-23	200-207	studies	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-24	208-209	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-25	210-217	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-26	218-219	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-27	220-223	via	_
1-28	224-227	the	_
1-29	228-236	regional	_
1-30	237-248	homogeneity	_
1-31	249-250	(	_
1-32	251-255	ReHo	_
1-33	256-257	)	_
1-34	258-264	method	_
1-35	265-269	have	_
1-36	270-282	demonstrated	_
1-37	283-295	inconsistent	_
1-38	296-299	and	_
1-39	300-311	conflicting	_
1-40	312-319	results	_
1-41	320-327	because	_
1-42	328-330	of	_
1-43	331-338	several	_
1-44	339-350	confounding	_
1-45	351-358	factors	_
1-46	359-360	,	_
1-47	361-365	such	_
1-48	366-368	as	_
1-49	369-374	small	_
1-50	375-381	sample	_
1-51	382-386	size	_
1-52	387-388	,	_
1-53	389-398	medicinal	_
1-54	399-408	influence	_
1-55	409-410	,	_
1-56	411-414	and	_
1-57	415-422	illness	_
1-58	423-431	duration	_
1-59	432-433	.	_

2-1	434-447	Relationships	_
2-2	448-455	between	_
2-3	456-460	ReHo	_
2-4	461-469	measures	_
2-5	470-473	and	_
2-6	474-483	cognitive	_
2-7	484-495	impairments	_
2-8	496-498	in	_
2-9	499-507	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-10	508-512	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-11	513-523	drug-naive	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
2-12	524-537	First-Episode	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
2-13	538-551	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
2-14	552-553	(	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
2-15	554-560	dn-FES	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
2-16	561-562	)	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
2-17	563-566	are	_
2-18	567-573	rarely	_
2-19	574-582	reported	_
2-20	583-584	.	_

3-1	585-589	This	_
3-2	590-595	study	_
3-3	596-599	was	_
3-4	600-609	conducted	_
3-5	610-612	to	_
3-6	613-620	explore	_
3-7	621-624	the	_
3-8	625-637	correlations	_
3-9	638-645	between	_
3-10	646-650	ReHo	_
3-11	651-659	measures	_
3-12	660-663	and	_
3-13	664-673	cognitive	_
3-14	674-682	deficits	_
3-15	683-686	and	_
3-16	687-695	clinical	_
3-17	696-704	symptoms	_
3-18	705-707	in	_
3-19	708-716	patients	_
3-20	717-721	with	_
3-21	722-728	dn-FES	_
3-22	729-730	.	_

4-1	731-738	Methods	_
4-2	739-740	A	_
4-3	741-746	total	_
4-4	747-749	of	_
4-5	750-752	69	_
4-6	753-761	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-7	762-766	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-8	767-773	dn-FES	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-9	774-777	and	_
4-10	778-780	74	_
4-11	781-788	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-12	789-797	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-13	798-802	were	_
4-14	803-812	recruited	_
4-15	813-814	.	_

5-1	815-822	MATRICS	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
5-2	823-832	Consensus	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
5-3	833-842	Cognitive	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
5-4	843-850	Battery	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
5-5	851-852	(	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
5-6	853-857	MCCB	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
5-7	858-859	)	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
5-8	860-861	,	_
5-9	862-870	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
5-10	871-876	Adult	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
5-11	877-889	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
5-12	890-895	Scale	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
5-13	896-897	(	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
5-14	898-902	WAIS	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
5-15	903-904	)	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
5-16	905-906	,	_
5-17	907-910	and	_
5-18	911-919	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
5-19	920-923	And	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
5-20	924-932	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
5-21	933-941	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
5-22	942-947	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
5-23	948-949	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
5-24	950-955	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
5-25	956-957	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
5-26	958-962	were	_
5-27	963-967	used	_
5-28	968-970	to	_
5-29	971-977	assess	_
5-30	978-987	cognitive	_
5-31	988-996	function	_
5-32	997-998	,	_
5-33	999-1011	Intelligence	_
5-34	1012-1020	Quotient	_
5-35	1021-1022	(	_
5-36	1023-1025	IQ	_
5-37	1026-1027	)	_
5-38	1028-1029	,	_
5-39	1030-1033	and	_
5-40	1034-1042	clinical	_
5-41	1043-1051	symptoms	_
5-42	1052-1053	,	_
5-43	1054-1066	respectively	_
5-44	1067-1068	.	_

6-1	1069-1072	The	_
6-2	1073-1085	correlations	_
6-3	1086-1093	between	_
6-4	1094-1098	ReHo	_
6-5	1099-1103	maps	_
6-6	1104-1107	and	_
6-7	1108-1117	cognitive	_
6-8	1118-1126	deficits	_
6-9	1127-1130	and	_
6-10	1131-1134	the	_
6-11	1135-1143	severity	_
6-12	1144-1146	of	_
6-13	1147-1155	symptoms	_
6-14	1156-1160	were	_
6-15	1161-1169	examined	_
6-16	1170-1175	using	_
6-17	1176-1182	strict	_
6-18	1183-1194	correlation	_
6-19	1195-1203	analysis	_
6-20	1204-1205	.	_

7-1	1206-1213	Results	_
7-2	1214-1218	ReHo	_
7-3	1219-1225	values	_
7-4	1226-1228	in	_
7-5	1229-1234	right	_
7-6	1235-1241	Middle	_
7-7	1242-1249	Frontal	_
7-8	1250-1255	Gyrus	_
7-9	1256-1257	(	_
7-10	1258-1261	MFG	_
7-11	1262-1263	)	_
7-12	1264-1267	and	_
7-13	1268-1276	Superior	_
7-14	1277-1284	Frontal	_
7-15	1285-1290	Gyrus	_
7-16	1291-1292	(	_
7-17	1293-1296	SFG	_
7-18	1297-1298	)	_
7-19	1299-1308	increased	_
7-20	1309-1311	in	_
7-21	1312-1318	dn-FES	_
7-22	1319-1324	group	_
7-23	1325-1326	,	_
7-24	1327-1334	whereas	_
7-25	1335-1339	ReHo	_
7-26	1340-1346	values	_
7-27	1347-1349	in	_
7-28	1350-1355	right	_
7-29	1356-1362	cuneus	_
7-30	1363-1372	decreased	_
7-31	1373-1374	.	_

8-1	1375-1386	Correlation	_
8-2	1387-1395	analysis	_
8-3	1396-1402	showed	_
8-4	1403-1407	that	_
8-5	1408-1411	the	_
8-6	1412-1416	ReHo	_
8-7	1417-1423	values	_
8-8	1424-1426	in	_
8-9	1427-1432	right	_
8-10	1433-1436	MFG	_
8-11	1437-1447	positively	_
8-12	1448-1458	correlated	_
8-13	1459-1463	with	_
8-14	1464-1483	attention/vigilance	_
8-15	1484-1495	impairments	_
8-16	1496-1497	,	_
8-17	1498-1504	social	_
8-18	1505-1514	cognition	_
8-19	1515-1523	deficits	_
8-20	1524-1525	,	_
8-21	1526-1529	and	_
8-22	1530-1533	the	_
8-23	1534-1542	severity	_
8-24	1543-1545	of	_
8-25	1546-1554	clinical	_
8-26	1555-1569	manifestations	_
8-27	1570-1571	.	_

9-1	1572-1583	Conclusions	_
9-2	1584-1589	These	_
9-3	1590-1598	findings	_
9-4	1599-1608	suggested	_
9-5	1609-1613	that	_
9-6	1614-1622	abnormal	_
9-7	1623-1634	spontaneous	_
9-8	1635-1645	activities	_
9-9	1646-1648	in	_
9-10	1649-1654	right	_
9-11	1655-1658	MFG	_
9-12	1659-1666	reflect	_
9-13	1667-1674	illness	_
9-14	1675-1683	severity	_
9-15	1684-1687	and	_
9-16	1688-1697	cognitive	_
9-17	1698-1706	deficits	_
9-18	1707-1708	,	_
9-19	1709-1714	which	_
9-20	1715-1719	also	_
9-21	1720-1725	serve	_
9-22	1726-1728	as	_
9-23	1729-1730	a	_
9-24	1731-1736	basis	_
9-25	1737-1740	for	_
9-26	1741-1753	establishing	_
9-27	1754-1763	objective	_
9-28	1764-1774	diagnostic	_
9-29	1775-1782	markers	_
9-30	1783-1786	and	_
9-31	1787-1792	might	_
9-32	1793-1795	be	_
9-33	1796-1797	a	_
9-34	1798-1806	clinical	_
9-35	1807-1819	intervention	_
9-36	1820-1826	target	_
9-37	1827-1830	for	_
9-38	1831-1839	treating	_
9-39	1840-1848	patients	_
9-40	1849-1853	with	_
9-41	1854-1867	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-42	1868-1869	.	_

10-1	1870-1877	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
10-2	1878-1890	Participants	_
10-3	1891-1903	Eighty-seven	_
10-4	1904-1912	patients	_
10-5	1913-1916	who	_
10-6	1917-1920	had	_
10-7	1921-1934	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
10-8	1935-1948	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
10-9	1949-1951	in	_
10-10	1952-1955	the	_
10-11	1956-1960	past	_
10-12	1961-1966	three	_
10-13	1967-1972	years	_
10-14	1973-1976	and	_
10-15	1977-1981	were	_
10-16	1982-1987	never	_
10-17	1988-1997	medicated	_
10-18	1998-2002	were	_
10-19	2003-2012	recruited	_
10-20	2013-2017	from	_
10-21	2018-2025	Nanjing	_
10-22	2026-2031	Brain	_
10-23	2032-2040	Hospital	_
10-24	2041-2045	from	_
10-25	2046-2053	January	_
10-26	2054-2058	2017	_
10-27	2059-2061	to	_
10-28	2062-2070	December	_
10-29	2071-2075	2018	_
10-30	2076-2077	.	_

11-1	2078-2088	Eighty-two	_
11-2	2089-2096	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-3	2097-2105	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-4	2106-2113	matched	_
11-5	2114-2116	in	_
11-6	2117-2122	terms	_
11-7	2123-2125	of	_
11-8	2126-2129	age	_
11-9	2130-2131	,	_
11-10	2132-2138	gender	_
11-11	2139-2142	and	_
11-12	2143-2152	ethnicity	_
11-13	2153-2157	were	_
11-14	2158-2167	recruited	_
11-15	2168-2172	from	_
11-16	2173-2176	the	_
11-17	2177-2181	same	_
11-18	2182-2186	area	_
11-19	2187-2194	through	_
11-20	2195-2206	advertising	_
11-21	2207-2208	.	_

12-1	2209-2212	The	_
12-2	2213-2220	general	_
12-3	2221-2230	inclusion	_
12-4	2231-2239	criteria	_
12-5	2240-2243	for	_
12-6	2244-2247	two	_
12-7	2248-2254	groups	_
12-8	2255-2259	were	_
12-9	2260-2265	right	_
12-10	2266-2272	handed	_
12-11	2273-2274	,	_
12-12	2275-2279	aged	_
12-13	2280-2285	16–45	_
12-14	2286-2287	,	_
12-15	2288-2291	and	_
12-16	2292-2296	able	_
12-17	2297-2299	to	_
12-18	2300-2310	understand	_
12-19	2311-2317	survey	_
12-20	2318-2330	instructions	_
12-21	2331-2334	and	_
12-22	2335-2342	execute	_
12-23	2343-2352	cognitive	_
12-24	2353-2358	tests	_
12-25	2359-2360	.	_

13-1	2361-2364	Two	_
13-2	2365-2374	qualified	_
13-3	2375-2383	clinical	_
13-4	2384-2397	psychologists	_
13-5	2398-2407	conducted	_
13-6	2408-2411	the	_
13-7	2412-2430	Mini-International	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
13-8	2431-2447	Neuropsychiatric	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
13-9	2448-2457	Interview	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
13-10	2458-2459	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
13-11	2460-2467	M.I.N.I	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
13-12	2468-2469	.	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
13-13	2470-2471	)	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale

14-1	2472-2474	to	_
14-2	2475-2482	confirm	_
14-3	2483-2492	diagnosis	_
14-4	2493-2497	with	_
14-5	2498-2501	the	_
14-6	2502-2508	DSM-IV	_
14-7	2509-2519	diagnostic	_
14-8	2520-2528	criteria	_
14-9	2529-2532	for	_
14-10	2533-2546	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
14-11	2547-2550	and	_
14-12	2551-2553	to	_
14-13	2554-2561	exclude	_
14-14	2562-2574	participants	_
14-15	2575-2579	with	_
14-16	2580-2581	a	_
14-17	2582-2589	history	_
14-18	2590-2592	of	_
14-19	2593-2602	affective	_
14-20	2603-2612	disorders	_
14-21	2613-2614	,	_
14-22	2615-2619	head	_
14-23	2620-2626	trauma	_
14-24	2627-2628	,	_
14-25	2629-2632	and	_
14-26	2633-2642	substance	_
14-27	2643-2648	abuse	_
14-28	2649-2650	.	_

15-1	2651-2658	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-2	2659-2667	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-3	2668-2672	were	_
15-4	2673-2677	also	_
15-5	2678-2689	interviewed	_
15-6	2690-2695	using	_
15-7	2696-2699	the	_
15-8	2700-2707	M.I.N.I	_
15-9	2708-2709	.	_

16-1	2710-2713	and	_
16-2	2714-2722	excluded	_
16-3	2723-2732	according	_
16-4	2733-2735	to	_
16-5	2736-2739	the	_
16-6	2740-2744	same	_
16-7	2745-2753	criteria	_
16-8	2754-2761	adopted	_
16-9	2762-2764	in	_
16-10	2765-2774	screening	_
16-11	2775-2783	patients	_
16-12	2784-2786	as	_
16-13	2787-2791	well	_
16-14	2792-2794	as	_
16-15	2795-2796	a	_
16-16	2797-2802	major	_
16-17	2803-2814	psychiatric	_
16-18	2815-2823	disorder	_
16-19	2824-2827	and	_
16-20	2828-2834	family	_
16-21	2835-2842	history	_
16-22	2843-2845	of	_
16-23	2846-2855	psychotic	_
16-24	2856-2864	disorder	_
16-25	2865-2866	.	_

17-1	2867-2870	The	_
17-2	2871-2876	study	_
17-3	2877-2880	was	_
17-4	2881-2889	approved	_
17-5	2890-2892	by	_
17-6	2893-2900	Nanjing	_
17-7	2901-2906	Brain	_
17-8	2907-2915	Hospital	_
17-9	2916-2922	Ethics	_
17-10	2923-2932	Committee	_
17-11	2933-2934	.	_

18-1	2935-2940	After	_
18-2	2941-2956	comprehensively	_
18-3	2957-2967	describing	_
18-4	2968-2971	and	_
18-5	2972-2982	explaining	_
18-6	2983-2986	the	_
18-7	2987-2992	study	_
18-8	2993-2994	,	_
18-9	2995-2996	a	_
18-10	2997-3004	written	_
18-11	3005-3013	informed	_
18-12	3014-3021	consent	_
18-13	3022-3025	was	_
18-14	3026-3034	obtained	_
18-15	3035-3039	from	_
18-16	3040-3044	each	_
18-17	3045-3056	participant	_
18-18	3057-3058	.	_

19-1	3059-3077	Neuropsychological	_
19-2	3078-3081	and	_
19-3	3082-3090	clinical	_
19-4	3091-3102	assessments	_
19-5	3103-3106	The	_
19-6	3107-3111	MCCB	_
19-7	3112-3115	was	_
19-8	3116-3120	used	_
19-9	3121-3123	to	_
19-10	3124-3130	assess	_
19-11	3131-3140	cognitive	_
19-12	3141-3149	function	_
19-13	3150-3151	.	_

20-1	3152-3155	The	_
20-2	3156-3163	present	_
20-3	3164-3169	study	_
20-4	3170-3178	included	_
20-5	3179-3183	nine	_
20-6	3184-3189	tasks	_
20-7	3190-3196	across	_
20-8	3197-3202	seven	_
20-9	3203-3212	cognitive	_
20-10	3213-3220	domains	_
20-11	3221-3222	,	_
20-12	3223-3232	including	_
20-13	3233-3238	speed	_
20-14	3239-3241	of	_
20-15	3242-3252	processing	_
20-16	3253-3254	(	_
20-17	3255-3263	Category	_
20-18	3264-3271	Fluency	_
20-19	3272-3273	,	_
20-20	3274-3280	Trails	_
20-21	3281-3282	A	_
20-22	3283-3284	,	_
20-23	3285-3290	Brief	_
20-24	3291-3301	Assessment	_
20-25	3302-3304	of	_
20-26	3305-3314	Cognition	_
20-27	3315-3317	in	_
20-28	3318-3331	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
20-29	3332-3338	Symbol	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
20-30	3339-3345	Coding	_
20-31	3346-3347	)	_
20-32	3348-3349	,	_
20-33	3350-3369	attention/vigilance	_
20-34	3370-3371	(	_
20-35	3372-3382	Continuous	_
20-36	3383-3394	Performance	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale
20-37	3395-3399	Test	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale
20-38	3400-3401	)	_
20-39	3402-3403	,	_
20-40	3404-3411	working	_
20-41	3412-3418	memory	_
20-42	3419-3420	(	_
20-43	3421-3429	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
20-44	3430-3436	Memory	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
20-45	3437-3446	Scale-III	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
20-46	3447-3454	Spatial	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
20-47	3455-3459	Span	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
20-48	3460-3461	)	_
20-49	3462-3463	,	_
20-50	3464-3470	verbal	_
20-51	3471-3479	learning	_
20-52	3480-3481	(	_
20-53	3482-3489	Hopkins	_
20-54	3490-3496	Verbal	_
20-55	3497-3505	Learning	http://maven.renci.org/NeuroBridge/neurobridge#II
20-56	3506-3518	Test–Revised	http://maven.renci.org/NeuroBridge/neurobridge#II
20-57	3519-3520	)	_
20-58	3521-3522	,	_
20-59	3523-3529	visual	_
20-60	3530-3538	learning	_
20-61	3539-3540	(	_
20-62	3541-3546	Brief	_
20-63	3547-3559	Visuospatial	_
20-64	3560-3566	Memory	_
20-65	3567-3579	Test–Revised	_
20-66	3580-3581	)	_
20-67	3582-3583	,	_
20-68	3584-3593	reasoning	_
20-69	3594-3597	and	_
20-70	3598-3605	problem	_
20-71	3606-3613	solving	_
20-72	3614-3615	(	_
20-73	3616-3619	The	_
20-74	3620-3625	Mazes	_
20-75	3626-3630	test	_
20-76	3631-3632	)	_
20-77	3633-3634	,	_
20-78	3635-3638	and	_
20-79	3639-3645	social	_
20-80	3646-3655	cognition	_
20-81	3656-3657	(	_
20-82	3658-3678	Mayer–Salovey–Caruso	_
20-83	3679-3688	Emotional	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
20-84	3689-3701	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
20-85	3702-3706	Test	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
20-86	3707-3708	)	_
20-87	3709-3710	.	_

21-1	3711-3713	We	_
21-2	3714-3723	corrected	_
21-3	3724-3727	the	_
21-4	3728-3736	original	_
21-5	3737-3742	score	_
21-6	3743-3746	for	_
21-7	3747-3750	age	_
21-8	3751-3752	,	_
21-9	3753-3759	gender	_
21-10	3760-3761	,	_
21-11	3762-3765	and	_
21-12	3766-3775	education	_
21-13	3776-3778	to	_
21-14	3779-3785	obtain	_
21-15	3786-3787	a	_
21-16	3788-3789	T	_
21-17	3790-3795	score	_
21-18	3796-3798	to	_
21-19	3799-3807	evaluate	_
21-20	3808-3817	cognitive	_
21-21	3818-3826	function	_
21-22	3827-3828	,	_
21-23	3829-3832	and	_
21-24	3833-3837	high	_
21-25	3838-3843	score	_
21-26	3844-3850	showed	_
21-27	3851-3852	a	_
21-28	3853-3857	good	_
21-29	3858-3869	performance	_
21-30	3870-3871	.	_

22-1	3872-3874	We	_
22-2	3875-3882	adopted	_
22-3	3883-3886	the	_
22-4	3887-3895	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
22-5	3896-3901	Adult	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
22-6	3902-3907	Scale	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
22-7	3908-3910	of	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
22-8	3911-3923	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
22-9	3924-3925	(	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
22-10	3926-3930	WAIS	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
22-11	3931-3932	)	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
22-12	3933-3935	to	_
22-13	3936-3940	test	_
22-14	3941-3944	the	_
22-15	3945-3957	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
22-16	3958-3966	Quotient	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
22-17	3967-3968	(	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
22-18	3969-3971	IQ	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
22-19	3972-3973	)	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
22-20	3974-3975	.	_

23-1	3976-3984	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
23-2	3985-3988	And	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
23-3	3989-3997	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
23-4	3998-4006	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
23-5	4007-4012	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
23-6	4013-4014	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
23-7	4015-4020	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
23-8	4021-4022	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
23-9	4023-4026	was	_
23-10	4027-4031	used	_
23-11	4032-4034	to	_
23-12	4035-4041	assess	_
23-13	4042-4050	symptoms	_
23-14	4051-4053	of	_
23-15	4054-4057	the	_
23-16	4058-4066	patients	_
23-17	4067-4068	,	_
23-18	4069-4072	and	_
23-19	4073-4076	the	_
23-20	4077-4084	process	_
23-21	4085-4088	was	_
23-22	4089-4096	carried	_
23-23	4097-4100	out	_
23-24	4101-4103	by	_
23-25	4104-4107	two	_
23-26	4108-4119	experienced	_
23-27	4120-4133	psychiatrists	_
23-28	4134-4135	.	_

24-1	4136-4141	Image	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
24-2	4142-4146	data	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
24-3	4147-4158	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
24-4	4159-4162	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
24-5	4163-4171	scanning	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
24-6	4172-4175	was	_
24-7	4176-4185	performed	_
24-8	4186-4190	with	_
24-9	4191-4192	a	_
24-10	4193-4200	Siemens	_
24-11	4201-4206	3.0-T	_
24-12	4207-4213	signal	_
24-13	4214-4221	scanner	_
24-14	4222-4223	,	_
24-15	4224-4227	and	_
24-16	4228-4229	a	_
24-17	4230-4238	standard	_
24-18	4239-4243	head	_
24-19	4244-4248	coil	_
24-20	4249-4255	padded	_
24-21	4256-4260	with	_
24-22	4261-4265	foam	_
24-23	4266-4269	was	_
24-24	4270-4274	used	_
24-25	4275-4277	to	_
24-26	4278-4284	reduce	_
24-27	4285-4289	head	_
24-28	4290-4296	motion	_
24-29	4297-4300	and	_
24-30	4301-4308	scanner	_
24-31	4309-4314	noise	_
24-32	4315-4316	.	_

25-1	4317-4320	All	_
25-2	4321-4323	of	_
25-3	4324-4327	the	_
25-4	4328-4340	participants	_
25-5	4341-4344	lay	_
25-6	4345-4347	in	_
25-7	4348-4349	a	_
25-8	4350-4356	supine	_
25-9	4357-4365	position	_
25-10	4366-4369	and	_
25-11	4370-4374	were	_
25-12	4375-4385	instructed	_
25-13	4386-4388	to	_
25-14	4389-4393	stay	_
25-15	4394-4399	still	_
25-16	4400-4401	,	_
25-17	4402-4407	close	_
25-18	4408-4413	their	_
25-19	4414-4418	eyes	_
25-20	4419-4420	,	_
25-21	4421-4425	keep	_
25-22	4426-4431	awake	_
25-23	4432-4433	,	_
25-24	4434-4437	and	_
25-25	4438-4441	let	_
25-26	4442-4447	their	_
25-27	4448-4452	mind	_
25-28	4453-4455	go	_
25-29	4456-4461	blank	_
25-30	4462-4463	.	_

26-1	4464-4481	Three-dimensional	_
26-2	4482-4493	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
26-3	4494-4502	sagittal	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
26-4	4503-4509	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
26-5	4510-4514	were	_
26-6	4515-4523	acquired	_
26-7	4524-4529	using	_
26-8	4530-4531	a	_
26-9	4532-4537	brain	_
26-10	4538-4544	volume	_
26-11	4545-4553	sequence	_
26-12	4554-4558	with	_
26-13	4559-4568	following	_
26-14	4569-4579	parameters	_
26-15	4580-4581	:	_
26-16	4582-4592	repetition	_
26-17	4593-4597	time	_
26-18	4598-4599	(	_
26-19	4600-4602	TR	_
26-20	4603-4604	)	_
26-21	4605-4606	=	_
26-22	4607-4611	2300	_
26-23	4612-4614	ms	_
26-24	4615-4616	,	_
26-25	4617-4621	echo	_
26-26	4622-4626	time	_
26-27	4627-4628	(	_
26-28	4629-4631	TE	_
26-29	4632-4633	)	_
26-30	4634-4635	=	_
26-31	4636-4640	2.96	_
26-32	4641-4643	ms	_
26-33	4644-4645	,	_
26-34	4646-4655	inversion	_
26-35	4656-4660	time	_
26-36	4661-4662	=	_
26-37	4663-4666	900	_
26-38	4667-4669	ms	_
26-39	4670-4671	,	_
26-40	4672-4676	flip	_
26-41	4677-4682	angle	_
26-42	4683-4684	(	_
26-43	4685-4687	FA	_
26-44	4688-4689	)	_
26-45	4690-4691	=	_
26-46	4692-4694	9°	_
26-47	4695-4696	,	_
26-48	4697-4702	field	_
26-49	4703-4705	of	_
26-50	4706-4710	view	_
26-51	4711-4712	(	_
26-52	4713-4716	FOV	_
26-53	4717-4718	)	_
26-54	4719-4720	=	_
26-55	4721-4724	256	_
26-56	4725-4727	mm	_
26-57	4728-4729	×	_
26-58	4730-4733	256	_
26-59	4734-4736	mm	_
26-60	4737-4738	,	_
26-61	4739-4745	matrix	_
26-62	4746-4747	=	_
26-63	4748-4751	256	_
26-64	4752-4753	×	_
26-65	4754-4757	256	_
26-66	4758-4759	,	_
26-67	4760-4765	slice	_
26-68	4766-4775	thickness	_
26-69	4776-4777	=	_
26-70	4778-4779	1	_
26-71	4780-4782	mm	_
26-72	4783-4784	,	_
26-73	4785-4788	192	_
26-74	4789-4797	sagittal	_
26-75	4798-4804	slices	_
26-76	4805-4806	,	_
26-77	4807-4810	and	_
26-78	4811-4822	acquisition	_
26-79	4823-4827	time	_
26-80	4828-4829	=	_
26-81	4830-4833	554	_
26-82	4834-4836	s.	_
26-83	4837-4840	The	_
26-84	4841-4847	images	_
26-85	4848-4852	were	_
26-86	4853-4861	acquired	_
26-87	4862-4867	using	_
26-88	4868-4869	a	_
26-89	4870-4878	gradient	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
26-90	4879-4883	echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
26-91	4884-4895	single-shot	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
26-92	4896-4900	echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
26-93	4901-4907	planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
26-94	4908-4915	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
26-95	4916-4924	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
26-96	4925-4929	with	_
26-97	4930-4933	the	_
26-98	4934-4943	following	_
26-99	4944-4954	parameters	_
26-100	4955-4956	:	_
26-101	4957-4962	TR/TE	_
26-102	4963-4964	=	_
26-103	4965-4972	2500/30	_
26-104	4973-4975	ms	_
26-105	4976-4977	,	_
26-106	4978-4981	FOV	_
26-107	4982-4983	=	_
26-108	4984-4987	224	_
26-109	4988-4990	mm	_
26-110	4991-4992	×	_
26-111	4993-4996	224	_
26-112	4997-4999	mm	_
26-113	5000-5001	,	_
26-114	5002-5008	matrix	_
26-115	5009-5010	=	_
26-116	5011-5013	64	_
26-117	5014-5015	×	_
26-118	5016-5018	64	_
26-119	5019-5020	,	_
26-120	5021-5023	FA	_
26-121	5024-5025	=	_
26-122	5026-5029	90°	_
26-123	5030-5031	,	_
26-124	5032-5037	slice	_
26-125	5038-5047	thickness	_
26-126	5048-5049	=	_
26-127	5050-5053	3.5	_
26-128	5054-5056	mm	_
26-129	5057-5058	,	_
26-130	5059-5061	no	_
26-131	5062-5065	gap	_
26-132	5066-5067	,	_
26-133	5068-5070	37	_
26-134	5071-5082	interleaved	_
26-135	5083-5093	transverse	_
26-136	5094-5100	slices	_
26-137	5101-5102	,	_
26-138	5103-5106	149	_
26-139	5107-5114	volumes	_
26-140	5115-5116	,	_
26-141	5117-5120	and	_
26-142	5121-5132	acquisition	_
26-143	5133-5137	time	_
26-144	5138-5139	=	_
26-145	5140-5143	379	_
26-146	5144-5146	s.	_
26-147	5147-5151	Data	_
26-148	5152-5165	preprocessing	_
26-149	5166-5169	and	_
26-150	5170-5180	processing	_
26-151	5181-5191	Functional	_
26-152	5192-5198	images	_
26-153	5199-5203	were	_
26-154	5204-5216	preprocessed	_
26-155	5217-5221	with	_
26-156	5222-5225	the	_
26-157	5226-5237	Matlab2013b	_
26-158	5238-5246	platform	_
26-159	5247-5250	and	_
26-160	5251-5254	the	_
26-161	5255-5259	Data	_
26-162	5260-5270	Processing	_
26-163	5271-5280	Assistant	_
26-164	5281-5284	for	_
26-165	5285-5292	rs-fMRI	_
26-166	5293-5294	(	_
26-167	5295-5304	DPARSF4.4	_
26-168	5305-5306	,	_
26-169	5307-5315	advanced	_
26-170	5316-5323	edition	_
26-171	5324-5325	)	_
26-172	5326-5327	.	_

27-1	5328-5332	Data	_
27-2	5333-5337	were	_
27-3	5338-5348	calculated	_
27-4	5349-5351	in	_
27-5	5352-5354	an	_
27-6	5355-5363	original	_
27-7	5364-5369	space	_
27-8	5370-5376	warped	_
27-9	5377-5379	by	_
27-10	5380-5393	diffeomorphic	_
27-11	5394-5404	anatomical	_
27-12	5405-5417	registration	_
27-13	5418-5425	through	_
27-14	5426-5439	exponentiated	_
27-15	5440-5443	Lie	_
27-16	5444-5451	algebra	_
27-17	5452-5453	(	_
27-18	5454-5460	DARTEL	_
27-19	5461-5462	)	_
27-20	5463-5464	.	_

28-1	5465-5468	The	_
28-2	5469-5474	first	_
28-3	5475-5479	four	_
28-4	5480-5487	volumes	_
28-5	5488-5490	of	_
28-6	5491-5494	the	_
28-7	5495-5499	BOLD	_
28-8	5500-5504	data	_
28-9	5505-5509	were	_
28-10	5510-5519	discarded	_
28-11	5520-5523	for	_
28-12	5524-5528	each	_
28-13	5529-5536	subject	_
28-14	5537-5539	to	_
28-15	5540-5545	allow	_
28-16	5546-5549	the	_
28-17	5550-5556	signal	_
28-18	5557-5559	to	_
28-19	5560-5565	reach	_
28-20	5566-5577	equilibrium	_
28-21	5578-5579	.	_

29-1	5580-5583	The	_
29-2	5584-5593	remaining	_
29-3	5594-5600	images	_
29-4	5601-5605	were	_
29-5	5606-5615	corrected	_
29-6	5616-5619	for	_
29-7	5620-5623	the	_
29-8	5624-5635	acquisition	_
29-9	5636-5640	time	_
29-10	5641-5646	delay	_
29-11	5647-5654	between	_
29-12	5655-5661	slices	_
29-13	5662-5663	.	_

30-1	5664-5667	All	_
30-2	5668-5670	of	_
30-3	5671-5674	the	_
30-4	5675-5683	subjects	_
30-5	5684-5690	should	_
30-6	5691-5695	have	_
30-7	5696-5698	no	_
30-8	5699-5700	>	_
30-9	5701-5702	2	_
30-10	5703-5705	mm	_
30-11	5706-5713	maximum	_
30-12	5714-5726	displacement	_
30-13	5727-5729	in	_
30-14	5730-5733	any	_
30-15	5734-5739	plane	_
30-16	5740-5741	,	_
30-17	5742-5744	2°	_
30-18	5745-5747	of	_
30-19	5748-5755	angular	_
30-20	5756-5762	motion	_
30-21	5763-5764	,	_
30-22	5765-5768	and	_
30-23	5769-5772	0.2	_
30-24	5773-5775	mm	_
30-25	5776-5780	mean	_
30-26	5781-5791	frame-wise	_
30-27	5792-5804	displacement	_
30-28	5805-5806	.	_

31-1	5807-5811	Then	_
31-2	5812-5813	,	_
31-3	5814-5817	the	_
31-4	5818-5824	images	_
31-5	5825-5829	were	_
31-6	5830-5839	spatially	_
31-7	5840-5849	realigned	_
31-8	5850-5852	to	_
31-9	5853-5856	the	_
31-10	5857-5862	first	_
31-11	5863-5868	image	_
31-12	5869-5871	of	_
31-13	5872-5876	each	_
31-14	5877-5884	dataset	_
31-15	5885-5886	,	_
31-16	5887-5890	and	_
31-17	5891-5899	movement	_
31-18	5900-5910	parameters	_
31-19	5911-5915	were	_
31-20	5916-5924	assessed	_
31-21	5925-5928	for	_
31-22	5929-5933	each	_
31-23	5934-5941	subject	_
31-24	5942-5945	and	_
31-25	5946-5955	corrected	_
31-26	5956-5961	using	_
31-27	5962-5965	the	_
31-28	5966-5973	Friston	_
31-29	5974-5976	24	_
31-30	5977-5985	approach	_
31-31	5986-5987	.	_

32-1	5988-5995	Several	_
32-2	5996-6004	nuisance	_
32-3	6005-6015	covariates	_
32-4	6016-6017	(	_
32-5	6018-6024	global	_
32-6	6025-6030	brain	_
32-7	6031-6032	,	_
32-8	6033-6038	white	_
32-9	6039-6045	matter	_
32-10	6046-6047	,	_
32-11	6048-6051	and	_
32-12	6052-6065	cerebrospinal	_
32-13	6066-6071	fluid	_
32-14	6072-6079	signals	_
32-15	6080-6081	)	_
32-16	6082-6086	were	_
32-17	6087-6096	regressed	_
32-18	6097-6098	.	_

33-1	6099-6102	The	_
33-2	6103-6111	datasets	_
33-3	6112-6116	were	_
33-4	6117-6126	band-pass	_
33-5	6127-6135	filtered	_
33-6	6136-6138	to	_
33-7	6139-6145	reduce	_
33-8	6146-6159	low-frequency	_
33-9	6160-6165	drift	_
33-10	6166-6169	and	_
33-11	6170-6184	high-frequency	_
33-12	6185-6198	physiological	_
33-13	6199-6210	respiratory	_
33-14	6211-6214	and	_
33-15	6215-6222	cardiac	_
33-16	6223-6228	noise	_
33-17	6229-6230	(	_
33-18	6231-6235	0.01	_
33-19	6236-6237	<	_
33-20	6238-6239	f	_
33-21	6240-6241	<	_
33-22	6242-6245	0.1	_
33-23	6246-6248	Hz	_
33-24	6249-6250	)	_
33-25	6251-6252	.	_

34-1	6253-6257	ReHo	_
34-2	6258-6261	was	_
34-3	6262-6272	calculated	_
34-4	6273-6275	on	_
34-5	6276-6277	a	_
34-6	6278-6292	voxel-by-voxel	_
34-7	6293-6298	basis	_
34-8	6299-6301	by	_
34-9	6302-6313	calculating	_
34-10	6314-6321	Kendall	_
34-11	6322-6323	’	_
34-12	6324-6325	s	_
34-13	6326-6337	coefficient	_
34-14	6338-6340	of	_
34-15	6341-6352	concordance	_
34-16	6353-6355	on	_
34-17	6356-6359	the	_
34-18	6360-6365	basis	_
34-19	6366-6368	of	_
34-20	6369-6377	regional	_
34-21	6378-6389	homogeneity	_
34-22	6390-6400	hypothesis	_
34-23	6401-6402	,	_
34-24	6403-6408	which	_
34-25	6409-6418	estimates	_
34-26	6419-6429	similarity	_
34-27	6430-6432	in	_
34-28	6433-6436	the	_
34-29	6437-6441	time	_
34-30	6442-6448	series	_
34-31	6449-6451	of	_
34-32	6452-6453	a	_
34-33	6454-6459	given	_
34-34	6460-6465	voxel	_
34-35	6466-6468	to	_
34-36	6469-6472	its	_
34-37	6473-6480	nearest	_
34-38	6481-6483	26	_
34-39	6484-6490	voxels	_
34-40	6491-6492	.	_

35-1	6493-6497	Each	_
35-2	6498-6505	subject	_
35-3	6506-6507	’	_
35-4	6508-6509	s	_
35-5	6510-6515	value	_
35-6	6516-6519	was	_
35-7	6520-6527	divided	_
35-8	6528-6530	by	_
35-9	6531-6534	the	_
35-10	6535-6539	mean	_
35-11	6540-6545	value	_
35-12	6546-6548	of	_
35-13	6549-6554	their	_
35-14	6555-6566	whole-brain	_
35-15	6567-6571	ReHo	_
35-16	6572-6574	to	_
35-17	6575-6584	eliminate	_
35-18	6585-6588	the	_
35-19	6589-6600	whole-brain	_
35-20	6601-6607	effect	_
35-21	6608-6610	to	_
35-22	6611-6614	the	_
35-23	6615-6621	utmost	_
35-24	6622-6628	extent	_
35-25	6629-6630	.	_

36-1	6631-6634	The	_
36-2	6635-6647	standardized	_
36-3	6648-6652	ReHo	_
36-4	6653-6659	images	_
36-5	6660-6664	were	_
36-6	6665-6674	spatially	_
36-7	6675-6683	smoothed	_
36-8	6684-6688	with	_
36-9	6689-6690	a	_
36-10	6691-6699	Gaussian	_
36-11	6700-6706	filter	_
36-12	6707-6711	with	_
36-13	6712-6713	a	_
36-14	6714-6718	full	_
36-15	6719-6724	width	_
36-16	6725-6727	at	_
36-17	6728-6732	half	_
36-18	6733-6740	maximum	_
36-19	6741-6742	(	_
36-20	6743-6747	FWHM	_
36-21	6748-6749	)	_
36-22	6750-6752	of	_
36-23	6753-6754	4	_
36-24	6755-6757	mm	_
36-25	6758-6759	.	_

37-1	6760-6767	Finally	_
37-2	6768-6769	,	_
37-3	6770-6774	ReHo	_
37-4	6775-6781	values	_
37-5	6782-6786	were	_
37-6	6787-6791	used	_
37-7	6792-6795	for	_
37-8	6796-6807	statistical	_
37-9	6808-6816	analysis	_
37-10	6817-6818	.	_

38-1	6819-6830	Statistical	_
38-2	6831-6839	analysis	_
38-3	6840-6851	Statistical	_
38-4	6852-6860	analysis	_
38-5	6861-6864	was	_
38-6	6865-6874	conducted	_
38-7	6875-6880	using	_
38-8	6881-6885	SPSS	_
38-9	6886-6894	software	_
38-10	6895-6896	(	_
38-11	6897-6908	version20.0	_
38-12	6909-6910	)	_
38-13	6911-6912	.	_

39-1	6913-6924	Demographic	_
39-2	6925-6928	and	_
39-3	6929-6937	clinical	_
39-4	6938-6947	variables	_
39-5	6948-6950	of	_
39-6	6951-6957	dn-FES	_
39-7	6958-6961	and	_
39-8	6962-6969	healthy	_
39-9	6970-6978	controls	_
39-10	6979-6983	were	_
39-11	6984-6992	compared	_
39-12	6993-6998	using	_
39-13	6999-7009	two-sample	_
39-14	7010-7016	t-test	_
39-15	7017-7020	for	_
39-16	7021-7031	continuous	_
39-17	7032-7041	variables	_
39-18	7042-7045	and	_
39-19	7046-7057	chi-squared	_
39-20	7058-7061	for	_
39-21	7062-7073	categorical	_
39-22	7074-7083	variables	_
39-23	7084-7085	.	_

40-1	7086-7092	F-test	_
40-2	7093-7096	was	_
40-3	7097-7101	used	_
40-4	7102-7105	for	_
40-5	7106-7110	data	_
40-6	7111-7119	analysis	_
40-7	7120-7122	of	_
40-8	7123-7132	cognitive	_
40-9	7133-7140	domains	_
40-10	7141-7146	after	_
40-11	7147-7153	taking	_
40-12	7154-7161	smoking	_
40-13	7162-7164	as	_
40-14	7165-7166	a	_
40-15	7167-7176	covariate	_
40-16	7177-7188	controlling	_
40-17	7189-7190	.	_

41-1	7191-7194	The	_
41-2	7195-7199	ReHo	_
41-3	7200-7204	maps	_
41-4	7205-7209	were	_
41-5	7210-7218	compared	_
41-6	7219-7226	between	_
41-7	7227-7230	the	_
41-8	7231-7234	two	_
41-9	7235-7241	groups	_
41-10	7242-7244	by	_
41-11	7245-7250	using	_
41-12	7251-7254	the	_
41-13	7255-7269	threshold-free	_
41-14	7270-7277	cluster	_
41-15	7278-7289	enhancement	_
41-16	7290-7291	(	_
41-17	7292-7296	TFCE	_
41-18	7297-7298	)	_
41-19	7299-7305	method	_
41-20	7306-7310	with	_
41-21	7311-7317	family	_
41-22	7318-7328	wise-error	_
41-23	7329-7330	(	_
41-24	7331-7334	FWE	_
41-25	7335-7336	)	_
41-26	7337-7347	correction	_
41-27	7348-7351	for	_
41-28	7352-7360	multiple	_
41-29	7361-7372	comparisons	_
41-30	7373-7374	.	_

42-1	7375-7378	Age	_
42-2	7379-7380	,	_
42-3	7381-7387	gender	_
42-4	7388-7389	,	_
42-5	7390-7399	education	_
42-6	7400-7401	,	_
42-7	7402-7405	and	_
42-8	7406-7417	probability	_
42-9	7418-7420	of	_
42-10	7421-7425	gray	_
42-11	7426-7432	matter	_
42-12	7433-7437	were	_
42-13	7438-7445	treated	_
42-14	7446-7448	as	_
42-15	7449-7459	covariates	_
42-16	7460-7461	,	_
42-17	7462-7465	and	_
42-18	7466-7469	the	_
42-19	7470-7479	threshold	_
42-20	7480-7483	for	_
42-21	7484-7496	significance	_
42-22	7497-7500	was	_
42-23	7501-7502	p	_
42-24	7503-7504	<	_
42-25	7505-7509	0.05	_
42-26	7510-7511	.	_

43-1	7512-7514	In	_
43-2	7515-7518	the	_
43-3	7519-7528	following	_
43-4	7529-7540	correlation	_
43-5	7541-7549	analysis	_
43-6	7550-7551	,	_
43-7	7552-7555	the	_
43-8	7556-7565	resultant	_
43-9	7566-7577	significant	_
43-10	7578-7582	ReHo	_
43-11	7583-7586	map	_
43-12	7587-7590	was	_
43-13	7591-7595	used	_
43-14	7596-7598	as	_
43-15	7599-7608	inclusion	_
43-16	7609-7613	mask	_
43-17	7614-7615	.	_

44-1	7616-7624	Patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
44-2	7625-7629	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
44-3	7630-7643	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
44-4	7644-7648	were	_
44-5	7649-7654	under	_
44-6	7655-7665	voxel-wise	_
44-7	7666-7677	correlation	_
44-8	7678-7686	analysis	_
44-9	7687-7689	to	_
44-10	7690-7697	explore	_
44-11	7698-7701	the	_
44-12	7702-7714	correlations	_
44-13	7715-7722	between	_
44-14	7723-7726	the	_
44-15	7727-7731	ReHo	_
44-16	7732-7736	maps	_
44-17	7737-7740	and	_
44-18	7741-7744	the	_
44-19	7745-7750	PANSS	_
44-20	7751-7752	(	_
44-21	7753-7761	positive	_
44-22	7762-7770	symptoms	_
44-23	7771-7772	,	_
44-24	7773-7781	negative	_
44-25	7782-7790	symptoms	_
44-26	7791-7792	,	_
44-27	7793-7800	general	_
44-28	7801-7802	,	_
44-29	7803-7806	and	_
44-30	7807-7810	all	_
44-31	7811-7817	totals	_
44-32	7818-7819	)	_
44-33	7820-7823	and	_
44-34	7824-7827	the	_
44-35	7828-7840	correlations	_
44-36	7841-7848	between	_
44-37	7849-7852	the	_
44-38	7853-7857	ReHo	_
44-39	7858-7862	maps	_
44-40	7863-7866	and	_
44-41	7867-7870	the	_
44-42	7871-7875	MCCB	_
44-43	7876-7877	(	_
44-44	7878-7883	speed	_
44-45	7884-7886	of	_
44-46	7887-7897	processing	_
44-47	7898-7899	,	_
44-48	7900-7906	verbal	_
44-49	7907-7915	learning	_
44-50	7916-7917	,	_
44-51	7918-7925	working	_
44-52	7926-7932	memory	_
44-53	7933-7934	,	_
44-54	7935-7952	reasoning/problem	_
44-55	7953-7960	solving	_
44-56	7961-7962	,	_
44-57	7963-7969	visual	_
44-58	7970-7978	learning	_
44-59	7979-7980	,	_
44-60	7981-8000	attention/vigilance	_
44-61	8001-8002	,	_
44-62	8003-8009	social	_
44-63	8010-8019	cognition	_
44-64	8020-8021	,	_
44-65	8022-8025	and	_
44-66	8026-8033	overall	_
44-67	8034-8043	composite	_
44-68	8044-8045	)	_
44-69	8046-8047	.	_

45-1	8048-8050	In	_
45-2	8051-8059	addition	_
45-3	8060-8061	,	_
45-4	8062-8065	age	_
45-5	8066-8067	,	_
45-6	8068-8074	gender	_
45-7	8075-8076	,	_
45-8	8077-8086	education	_
45-9	8087-8088	,	_
45-10	8089-8096	illness	_
45-11	8097-8105	duration	_
45-12	8106-8109	and	_
45-13	8110-8113	the	_
45-14	8114-8119	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
45-15	8120-8125	total	_
45-16	8126-8131	score	_
45-17	8132-8136	were	_
45-18	8137-8143	placed	_
45-19	8144-8146	in	_
45-20	8147-8150	the	_
45-21	8151-8156	model	_
45-22	8157-8159	as	_
45-23	8160-8170	covariates	_
45-24	8171-8172	.	_

46-1	8173-8176	The	_
46-2	8177-8194	permutation-based	_
46-3	8195-8208	nonparametric	_
46-4	8209-8218	inference	_
46-5	8219-8222	was	_
46-6	8223-8233	undertaken	_
46-7	8234-8238	with	_
46-8	8239-8243	5000	_
46-9	8244-8256	permutations	_
46-10	8257-8258	,	_
46-11	8259-8262	and	_
46-12	8263-8275	significance	_
46-13	8276-8281	level	_
46-14	8282-8285	was	_
46-15	8286-8297	thresholded	_
46-16	8298-8301	for	_
46-17	8302-8305	the	_
46-18	8306-8316	correction	_
46-19	8317-8319	of	_
46-20	8320-8328	multiple	_
46-21	8329-8340	comparisons	_
46-22	8341-8343	by	_
46-23	8344-8349	using	_
46-24	8350-8351	a	_
46-25	8352-8356	TFCE	_
46-26	8357-8359	of	_
46-27	8360-8364	0.05	_
46-28	8365-8366	.	_

47-1	8367-8379	Availability	_
47-2	8380-8382	of	_
47-3	8383-8387	data	_
47-4	8388-8391	and	_
47-5	8392-8401	materials	_
47-6	8402-8405	The	_
47-7	8406-8410	data	_
47-8	8411-8415	sets	_
47-9	8416-8420	used	_
47-10	8421-8424	and	_
47-11	8425-8428	/or	_
47-12	8429-8437	analyzed	_
47-13	8438-8444	during	_
47-14	8445-8448	the	_
47-15	8449-8456	present	_
47-16	8457-8462	study	_
47-17	8463-8466	are	_
47-18	8467-8476	available	_
47-19	8477-8481	from	_
47-20	8482-8485	the	_
47-21	8486-8499	corresponding	_
47-22	8500-8506	author	_
47-23	8507-8509	on	_
47-24	8510-8520	reasonable	_
47-25	8521-8528	request	_
47-26	8529-8530	.	_

48-1	8531-8537	Ethics	_
48-2	8538-8546	approval	_
48-3	8547-8550	and	_
48-4	8551-8558	consent	_
48-5	8559-8561	to	_
48-6	8562-8573	participate	_
48-7	8574-8577	All	_
48-8	8578-8586	research	_
48-9	8587-8597	procedures	_
48-10	8598-8602	were	_
48-11	8603-8611	approved	_
48-12	8612-8614	by	_
48-13	8615-8618	the	_
48-14	8619-8626	Medical	_
48-15	8627-8635	Research	_
48-16	8636-8642	Ethics	_
48-17	8643-8652	Committee	_
48-18	8653-8655	of	_
48-19	8656-8663	Nanjing	_
48-20	8664-8669	Brain	_
48-21	8670-8678	Hospital	_
48-22	8679-8680	,	_
48-23	8681-8684	and	_
48-24	8685-8689	were	_
48-25	8690-8699	conducted	_
48-26	8700-8702	in	_
48-27	8703-8713	accordance	_
48-28	8714-8718	with	_
48-29	8719-8722	the	_
48-30	8723-8727	1964	_
48-31	8728-8736	Helsinki	_
48-32	8737-8748	declaration	_
48-33	8749-8752	and	_
48-34	8753-8756	its	_
48-35	8757-8762	later	_
48-36	8763-8773	amendments	_
48-37	8774-8775	.	_

49-1	8776-8783	Written	_
49-2	8784-8792	informed	_
49-3	8793-8800	consent	_
49-4	8801-8803	of	_
49-5	8804-8807	the	_
49-6	8808-8821	schizophrenic	_
49-7	8822-8829	patient	_
49-8	8830-8833	was	_
49-9	8834-8842	obtained	_
49-10	8843-8847	from	_
49-11	8848-8855	his/her	_
49-12	8856-8863	legally	_
49-13	8864-8874	authorized	_
49-14	8875-8889	representative	_
49-15	8890-8893	and	_
49-16	8894-8897	the	_
49-17	8898-8905	control	_
49-18	8906-8914	provided	_
49-19	8915-8922	written	_
49-20	8923-8931	informed	_
49-21	8932-8939	consent	_
49-22	8940-8955	himself/herself	_
49-23	8956-8961	after	_
49-24	8962-8969	totally	_
49-25	8970-8983	understanding	_
49-26	8984-8987	the	_
49-27	8988-8995	purpose	_
49-28	8996-8998	of	_
49-29	8999-9002	our	_
49-30	9003-9008	study	_
49-31	9009-9010	.	_

50-1	9011-9018	Consent	_
50-2	9019-9022	for	_
50-3	9023-9034	publication	_
50-4	9035-9038	Not	_
50-5	9039-9049	applicable	_
50-6	9050-9051	.	_

